Metharbital
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Metharbital was patented in 1905 by Emil Fischer working for Merck.[1] It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy. It has similar properties to phenobarbital.
History
History
- 1952 Gemonil was introduced by Abbott Laboratories.
- 1990 Abbott stopped marketing.
Synthesis
Synthesis
![700px[2][3] U.S. Patent 782,742](https://www.wikidoc.org/index.php/File%3AMetharbital_syn.png)
In an interesting variation on this theme (cf hexobarbital), the bis acid chloride of diethylmalonate (1) is condensed with the O-methyl ether of urea (2, Methyl carbamimidate[4]) to afford the imino ether of the barbituric acid (3). Heating this ether at 200°C results in O to N migration of the methyl group and formation of metharbital 4.
References
References
- ↑ US Patent 782742
- ↑ A. Halpern, J.W. Jones, J. Am. Pharm. Assoc., 38, 352 (1949).
- ↑ Template:Cite doi
- ↑ http://www.chemspider.com/Chemical-Structure.68069.html?rid=81ad3137-afb0-456a-8c9f-d6c73ada4966
- The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
- The Comparative Toxicogenomics Database: Metharbital
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH